Use, tolerability and compliance of spironolactone in the treatment of heart failure
Tóm tắt
Từ khóa
Tài liệu tham khảo
McKelvie R: Heart Failure. Clinical Evidence. Electronic source. 2009, Access date: 2011-04-21, [ http://www.clinicalevidence.bmj.com ]
Arnold JM, Liu P, Demers C, Dorian P, Giannetti N, Haddad H, Heckman GA, Howlett JG, Ignaszewski A, Johnstone DE, Jong P, McKelvie RS, Moe GW, Parker JD, Rao V, Ross HJ, Sequeira EJ, Svendsen AM, Teo K, Tsuyuki RT, White M: Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol. 2006, 22 (1): 23-45. 10.1016/S0828-282X(06)70237-9.
Ross H, Howlett J, Arnold JM, Liu P, O'Neill BJ, Brophy JM, Simpson CS, Sholdice MM, Knudtson M, Ross DB, Rottger J, Glasgow K: Treating the right patient at the right time: access to heart failure care. Can J Cardiol. 2006, 22 (9): 749-754. 10.1016/S0828-282X(06)70290-2.
Martineau P, Frenette M, Blais L, Sauve C: Multidisciplinary outpatient congestive heart failure clinic: impact on hospital admissions and emergency room visits. Can J Cardiol. 2004, 20 (12): 1205-1211.
Public Health Agency of Canada: Tracking Heart Disease and Stroke in Canada. 2009, Ottawa
Kaul P, McAlister FA, Ezekowitz JA, Bakal JA, Curtis LH, Quan H, Knudtson ML, Armstrong PW: Resource use in the last 6 months of life among patients with heart failure in Canada. Arch Intern Med. 2011, 171 (3): 211-217. 10.1001/archinternmed.2010.365.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999, 341 (10): 709-717. 10.1056/NEJM199909023411001.
Struthers AD: Impact of aldosterone on vascular pathophysiology. Congest Heart Fail. 2002, 8 (1): 18-22. 10.1111/j.1527-5299.2002.00722.x.
Weber KT: Aldosterone and spironolactone in heart failure. N Engl J Med. 1999, 341 (10): 753-755. 10.1056/NEJM199909023411009.
Bouvy ML, Heerdink ER, Herings RM: Long-term therapy with spironolactone. Pharm World Sci. 2001, 23 (4): 132-134. 10.1023/A:1011859702495.
Wrenger E, Muller R, Moesenthin M, Welte T, Frolich JC, Neumann KH: Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ. 2003, 327 (7407): 147-149. 10.1136/bmj.327.7407.147.
Gearry RB, Richardson AK, Frampton CM, Dodgshun AJ, Barclay ML: Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol. 2010, 25 (2): 325-333. 10.1111/j.1440-1746.2009.06140.x.
Nikolaus S, Schreiber S: Diagnostics of inflammatory bowel disease. Gastroenterology. 2007, 133 (5): 1670-1689. 10.1053/j.gastro.2007.09.001.
Von Korff M, Wagner EH, Saunders K: A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992, 45 (2): 197-203. 10.1016/0895-4356(92)90016-G.
Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol. 1996, 78 (8): 902-907.
Hay E, Derazon H, Bukish N, Katz L, Kruglyakov I, Armoni M: Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet. J Emerg Med. 2002, 22 (4): 349-352. 10.1016/S0736-4679(02)00434-1.
Webster J: Interactions of NSAIDs with diuretics and beta-blockers mechanisms and clinical implications. Drugs. 1985, 30 (1): 32-41. 10.2165/00003495-198530010-00004.
Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ, Hawkes AL: Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006. Med J Aust. 2006, 185 (10): 549-557.
Poole-Wilson PA: The Cardiac Insufficiency Bisoprolol Study II. Lancet. 1999, 353 (9161): 1360-1361.